(May 22 2024, Kunming) Walvax Biotechnology Co., Ltd. ("Walvax", stock code: 300142.SZ) participated in the Road to the 3rd World Local Production Forum 2025 session during Annual Investment Meeting (AIM) Congress 2024 held in Abu-Dhabi, the United Arab Emirates, from May 7 to 9, 2024. Dr. Shaozhong Dong, Vice President of Walvax, shared the company's insights and experience as an emerging biopharma in promoting local vaccine production at the session on May 7.

The WHO session during AIM Congress 2024, titled "The Road to the 3rd World Local Production Forum 2025", provided an opportunity for stakeholders to share insights and recommendations that will shape the agenda and outcomes of the forthcoming World Local Production Forum (WLPF). The session included presentations, panel discussions, and interactions among academia, government officials, industry executives, and other key players in the health sector.

In the session on May 7, Dr. Jicui Dong, representing the WLPF Secretariat at the World Health Organization, set the stage with a welcome note, emphasising the importance of collaborative efforts in ensuring access to essential medicines and health products. Keynote speaker Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health in Abu Dhabi, underscored the significance of equitable pathways and innovative strategies for a healthier future.

The panel discussion, featured eminent figures from Egypt, China, South Africa, Morocco, and the USA, who deliberated on the key highlights and priorities for the upcoming 3rd World Local Production Forum. Dr. Shaozhong Dong, Vice President of Walvax, shared Walvax's tremendous progress and remarkable achievements in promoting local production, and outlined Walvax's plans to further strengthen efforts in assisting partners to bring locally made products to market faster. He emphasized various governments, non-governmental organizations (NGOs), and multilateral organizations are required to intervene, to ensure that the public health benefits of vaccines are fully realized.

(From left to right, Dr Jicui Dong, Head of the Local Production and Assistance Unit at the World Health Organization (WHO); Dr Jian Dong, Chief Executive Officer at the WuXi Vaccines; Dr Hatem Amer, Associate Minister of Health and Population for International Relations, Egypt; Prof. Frederick Abbott, Edward Ball Eminent Scholar Professor of Law, College of Law, Florida States University; Prof. Abderrahmane Maaroufi, Director of the Centre de Sérums et Vaccins (Institut Pasteur du Maroc); Dr Shaozhong Dong, Vice President, Walvax, Biotechnology Co. Ltd China)

Through this participation in the Road to the 3rd World Local Production Forum 2025 session during the AIM Congress 2024, Walvax aimed to collaborate with global stakeholders on advancing equitable access to vaccines and other essential health products. The company recognizes the importance of vaccine manufacturing capabilities in developing countries and the immense challenges that lie ahead. Walvax remains dedicated to playing a constructive role in collective efforts to strengthen global health.

About Walvax

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer in China, and has engaged in research and development, manufacture and distribution of safe and efficacious vaccines. Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 with ticker symbol of 300142.SZ and has started business expansion from traditional vaccines to innovative vaccines since then. As of October 2022, Walvax has successfully developed and commercialized 9 vaccines with a total of 13 presentations (vial and/or prefilled syringe), including SARS-CoV-2 mRNA vaccine (AWcorna), 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV-13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV-2). For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.